A dexamethasone-sparing regimen involving lenalidomide (Revlimid) and the anti-CD38 drug daratumumab (Darzalex) was safe and ...

Lenalidomide is a cornerstone therapy for multiple myeloma (MM) and other hematologic malignancies, but conventional oral dosing is limited by high peak plasma concentrations, rapid clearance, and ...

Low-dose nivolumab (Opdivo) plus lenalidomide (Revlimid) yielded a promising response with a favorable safety profile in patients with classical Hodgkin lymphoma (cHL), according to a single-arm phase ...

Gabrail Cancer & Research Center activated and open to screen patients, with Nash Gabrail, MD as lead investigator Second site, Regional Medical Oncology Center, also activated Recent Phase 1b ...

Lupin has received approval from the Food and Drug Administration for lenalidomide capsules, 2.5 mg, 5 mg, 10 mg, 15 mg, 20 mg and 25 mg, which are the generic of Bristol-Myers Squibb's Revlimid. The ...

Revlimid (lenalidomide) is a brand-name drug that doctors may prescribe to treat certain cancers of the blood. If a person has a Medicare Part D prescription drug plan or a Medicare Advantage (Part C) ...

"We are well aware that four-drug regimens with anti-CD38 monoclonal antibodies, lenalidomide, proteasome inhibitors, and dexamethasone are a standard for newly diagnosed multiple myeloma, ...

Lupin has bagged the approval for Lenalidomide capsules. This drug is used in the treatment of Multiple Myeloma (MM). In an exchange filing, the company announced that it has received approval for its ...